INDIANA – Indiana will receive $6.25 million as part of a settlement with global pharmaceutical companies over allegations that they conspired to increase the price of a prescription device called EpiPen by more than 600% on Hoosier consumers. The product is used to inject adrenaline into patients to combat severe allergic reactions.
“Some pharmaceutical companies have prioritized profits over patients,” Attorney General Todd Rokita said. “But by demonstrating there are severe penalties for unlawful tactics to overcharge Hoosiers, we can deter this kind of conduct in the future.”
In January of 2025, Attorney General Rokita filed an antitrust lawsuit alleging that Viatris Inc., Pfizer Inc., and other companies conspired to raise prices to maximize revenue from EpiPen prescriptions and to prevent other similar products from reaching the market and becoming available to consumers. Viatris was formed in 2020 through the merger of Mylan and Upjohn, a Pfizer subsidiary.
The complaint alleged that the companies and their subsidiaries violated the Indiana Deceptive Consumer Sales Act, the Indiana Antitrust Act, and the Medicaid False Claims Act by continually increasing the price of EpiPens and by paying pharmacy benefit managers (PBMs) to exclude competition…